Quantcast

Latest Amgen Stories

2014-03-05 16:26:34

THOUSAND OAKS, Calif., March 5, 2014 /PRNewswire/ -- Amgen (NASDAQ:AMGN) announced that its Board of Directors today declared a $0.61 per share dividend for the second quarter of 2014. The dividend will be paid on June 6, 2014, to all stockholders of record as of the close of business on May 15, 2014. About Amgen Amgen is committed to unlocking the potential of biology for patients suffering from serious illnesses by discovering, developing, manufacturing and delivering...

2014-03-01 16:20:28

THOUSAND OAKS, Calif., March 1, 2014 /PRNewswire/ -- Amgen (NASDAQ:AMGN) will present at the Cowen and Company 34(th) Annual Healthcare Conference at 2:10 p.m. ET on Monday, Mar. 3, 2014, at the Boston Marriott Copley Place in Boston. Anthony C. Hooper, executive vice president of Global Commercial Operations at Amgen, will present at the conference. Live audio of the presentation can be accessed from the Events Calendar on Amgen's website, www.amgen.com, under Investors. A replay of...

2014-02-25 23:24:42

MarketOptimizer.org offers “PharmaPoint: Osteoporosis - Global Drug Forecast and Market Analysis to 2022” research report in its store. Dallas, TX (PRWEB) February 25, 2014 Switch to Anabolics Driving Osteoporosis Market Growth A major paradigm shift in late and mid-stage product development from anti-resorptive therapies to anabolic drugs will prove the key driver in the global osteoporosis market. The new report* forecasts that the combined osteoporosis therapeutics market of the...

2014-02-21 16:23:04

THOUSAND OAKS, Calif., Feb. 21, 2014 /PRNewswire/ -- Amgen (NASDAQ: AMGN) will present at the RBC Capital Markets' Global Healthcare Conference at 4:05 p.m. ET on Wednesday, Feb. 26, 2014, at the New York Palace Hotel in New York City. Arvind Sood, vice president of Investor Relations at Amgen, will present at the conference. Live audio of the presentation can be accessed from the Events Calendar on Amgen's website, www.amgen.com, under Investors. A replay of the webcast will also be...

2014-02-19 08:34:21

BURNABY, BC, Feb. 19, 2014 /PRNewswire/ - Innovative Targeting Solutions Inc. (ITS), the developer of the next generation protein engineering technology (HuTARG(TM)), today announced the extension of its research collaboration with Amgen Inc. (Thousand Oaks, CA) that allows Amgen to internalize ITS' HuTARG(TM) technology. Under the terms of the agreement, ITS is entitled to specific license payments and development milestones. About Innovative Targeting Solutions Inc. Founded in...

2014-02-11 12:25:31

DUBLIN, February 11, 2014 /PRNewswire/ -- Research and Markets ( http://www.researchandmarkets.com/research/6mkhtx/biosimilars) has announced the addition of the "Biosimilars Market by Product & Application - Global Forecast to 2018" [http://www.researchandmarkets.com/research/6mkhtx/biosimilars ] report to their offering. (Logo: http://photos.prnewswire.com/prnh/20130307/600769 ) The global market is segmented on the basis of products, applications, and...

2014-02-05 08:28:16

THOUSAND OAKS, Calif., Feb. 5, 2014 /PRNewswire/ -- Amgen (NASDAQ:AMGN) and Merck, known as MSD outside the United States and Canada, announced today that they have entered into an agreement through a subsidiary to evaluate the safety and efficacy of talimogene laherparepvec, an investigational oncolytic immunotherapy, combined with MK-3475, an investigational anti-PD-1 immunotherapy, in a Phase 1b/2 study of patients with mid- to late-stage melanoma. "Talimogene laherparepvec has...

2014-01-30 16:26:43

RUTHERFORD-2 Study Meets Co-Primary Endpoints of LDL Cholesterol Reduction THOUSAND OAKS, Calif., Jan. 30, 2014 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced that the Phase 3 RUTHERFORD-2 (RedUction of LDL-C with PCSK9 InhibiTion in HEteRozygous Familial HyperchOlesteRolemia Disorder Study-2) trial evaluating evolocumab in combination with statins and other lipid-lowering therapies in patients with heterozygous familial hypercholesterolemia (HeFH) met its co-primary...

2014-01-29 23:32:09

Introducing CE-IVD marked kits with expanded mutation coverage in colorectal cancer for Kras, Nras, and Braf genes. Tarzana, Calif (PRWEB) January 29, 2014 Today EntroGen (http://www.entrogen.com) announced immediate availability of its expanded colorectal cancer screening products. EntroGen K-Ras and N-Ras Mutation Analysis kits have been updated to include coverage for exon 2, 3 and 4 mutations in both genes. The Company has obtained a CE-IVD mark for these products. The importance of...

2014-01-28 16:26:04

Study Meets Co-Primary Endpoints of LDL Cholesterol Reduction THOUSAND OAKS, Calif., Jan. 28, 2014 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced that the Phase 3 LAPLACE-2 (LDL-C Assessment with PCSK9 MonoclonaL Antibody Inhibition Combined with Statin ThErapy-2) trial evaluating evolocumab in combination with statin therapy in patients with high cholesterol met its co-primary endpoints: the percent reduction from baseline in low-density lipoprotein cholesterol (LDL-C) at week...


Word of the Day
lambent
  • Licking.
  • Hence Running along or over a surface, as if in the act of licking; flowing over or along; lapping or bathing; softly bright; gleaming.
This word comes the Latin 'lambere,' to lick.
Related